pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

PFIZER

USupdated 6mo ago
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0

Pipeline(0)

no pipeline products on record

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • phase1A Study to Learn About the Study Medicine Called PF-08165784 in People With PIK3CA-Mutated Advanced or Metastatic Solid Tumorsnot yet recruitingn=268
  • phase3A Continuation Study of Tilrekimig in Adults With Moderate-to-Severe Long-Term Breathing Difficulty, Known by the Medical Term of Chronic Obstructive Pulmonary Disease (COPD) to Learn About This Medicine When Used for a Long Period of Timerecruitingn=1,360
  • phase3A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areatarecruitingn=674
  • phase3A Study of Sasanlimab in People With Non-muscle Invasive Bladder Canceractive not recruitingn=1,068
  • phase3A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Canceractive not recruitingn=624
  • phase3Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy and With Tarlatamab, Alone or With Chemotherapy, in Adult Participants With Extensive-Stage Small Cell Lung Cancerrecruitingn=550
  • —A Study to Learn About the Study Medicine (Called Marstacimab) in People With Hemophilia A or Brecruitingn=100
  • phase1A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors.recruitingn=280
🐶 Hiring Signal
No open roles indexed yet — view PFIZER jobs →

News

  • nChroma halves workforce, BioXcel lets execs go
    Follow along as BioSpace tracks job cuts and restructuring initiatives.
    biospace · 4h ago
  • 9 biotechs will cut at least half their California workforces
    Workforce reductions have hit over 1,000 biopharma employees in The Golden State year to date, with pink slips coming from small biotechs and large pharmas. Biotechs have been hit the hardest, with…
    biospace · 14h ago
  • Pfizer leaps into ‘in vivo’ CAR-T with latest China deal
    The potentially $2.6 billion collaboration puts Pfizer into a competitive race to treat autoimmune conditions by reprogramming cells inside the body.
    biopharma_dive · 1d ago
  • Government actions are hitting smaller biotechs the hardest: Report
    Layoffs at the FDA, disruptions to research funding and increased tariffs led the investment banking firm Cassel Salpeter to wonder whether the government is strangling the biotech industry.
    biospace · 1d ago
  • FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK
    The FDA had several issues with ivonescimab, according to the letter. Elsewhere, Sellas shares rocketed on results for a leukemia vaccine and Biogen and Lilly struck up new R&D pacts.
    biopharma_dive · 1d ago
  • Pfizer launches into autoimmune CAR T with China's Starna in up to $2.6B deal
    The Chinese biotech will work with Pfizer on three in vivo CAR T therapies for autoimmune indications.
    biospace · 1d ago
  • In China’s shadow, Pfizer CEO calls for AI savings to bolster Big Pharma
    Speaking at the Jefferies conference in London, Pfizer CEO Albert Bourla warned of China’s rise and spoke to how companies like his can compete by leveraging AI-discovered savings.
    biospace · 1d ago
  • Summit’s rejection letter reveals FDA’s deeper concerns about trial design, safety
    Summit Therapeutics was warned twice by the FDA that the Phase 3 trial used to support the application for ivonescimab did not include patients that accurately represented the American population.
    biospace · 1d ago
  • Pfizer gets into in vivo CAR-T through licensing deal with Starna Therapeutics
    Pfizer is entering the in vivo CAR-T race, paying $330 million upfront to Starna Therapeutics. The deal gives Pfizer exclusive rights outside of Greater China to three pre-IND assets in autoimmune…
    endpoints · 1d ago
  • Summit’s rejection, Isomorphic’s record $5B raise, obesity and Alzheimer’s in the spotlight
    The FDA declined to approve Summit Therapeutics’ Akeso-partnered ivonescimab, putting other PD-1/VEGF drug developers on notice; Isomorphic bagged a $5 billion series C, the largest in biotech hist…
    biospace · 1d ago
view all news mentions →
identifiers
country
US
source
openfda_drugsfda
mentioned in
10news items
entity-linker matched

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?